

Role of p53 β in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53

WANSHENG JI^{1*}, JINGRONG MA^{2*}, HONGMEI ZHANG¹, HUA ZHONG¹,
LEI LI¹, NA DING¹, JIANXIN JIAO¹ and ZHIXING GAO¹

¹Department of Gastroenterology, Affiliated Hospital of Weifang Medical University;

²Graduate School of Weifang Medical University, Weifang, Shandong 261031, P.R. China

Received February 23, 2014; Accepted November 21, 2014

DOI: 10.3892/mmr.2015.3370

Abstract. p53 is a tumor suppressor gene whose mutation is highly associated with tumorigenesis. The present study investigated the role of p53 β in the inhibition of proliferation of gastric cancer cell lines expressing wild-type or mutated p53. Wild-type p53 is expressed in MKN45 cells, but deleted in KATOIII cells, whereas mutated p53 is expressed in SGC7901 cells. The mRNA expression levels of p53 β and Δ 133p53 were detected in MKN45, SGC-7901 and KATOIII gastric cancer cell lines using nested polymerase chain reaction (PCR). The mRNA expression levels of p53, p53 β and B-cell lymphoma 2-associated X protein (Bax) were detected in the MKN45 and SGC-7901 cells following treatment with cisplatin by reverse transcription-PCR. The inhibition of cellular proliferation following treatment with cisplatin was measured by MTT assay. The results of the present study demonstrated that both p53 β and Δ 133p53 mRNA were expressed in the MKN45 cells, whereas only p53 β mRNA was expressed in the SGC7901 cells. No expression of p53 β or Δ 133p53 mRNA was detected in the KATOIII cells. Following treatment with cisplatin, the number of both MKN45 and SGC-7901 cells was significantly reduced ($P < 0.001$). In the MKN45 cells, p53 β , p53 and Bax mRNA expression levels gradually increased with the dose of cisplatin, and the expression of p53 β was positively correlated with the expression of p53 ($r_s = 6.358$, $P < 0.05$) and Bax ($r_s = 8.023$, $P < 0.05$). In the SGC-7901 cells, the expression levels of p53 β , p53 and Bax mRNA did not alter with the dose of cisplatin, and the expression of p53 β was positively correlated to the expression of p53 ($r_s = 26.41$, $P < 0.01$) but not that of Bax. The present study identified the different

roles of the p53 β isoform in gastric cancer cells with different p53 backgrounds. Enhanced knowledge regarding the p53 status is required for the development of specific biological therapies against gastric cancer.

Introduction

p53 is a tumor suppressor gene whose mutation status is highly associated with tumorigenesis. Through regulating the transcription of effector molecules, such as B-cell lymphoma 2-associated X protein (Bax), mouse double minute 2 homolog (MDM2), and phosphatase and tensin homolog, p53 is involved in cell cycle arrest, DNA repair and apoptosis (1-3). Besides wild-type p53, other protein isoforms of p53 are expressed under physical and pathological conditions due to promoter selection, alternative splicing and the selection of translation initiators (4-6). The alternative splicing sites and promoters of p53 are presented in the diagram of the human TP53 gene structure (Fig. 1A), and possible p53 protein isoforms are listed in Fig. 1B. Theoretically, ≥ 12 isoforms of p53 may be produced by alternative splicing and the selection of different promoters, including p53, p53 β , p53 γ , Δ 40p53, Δ 40p53 β , Δ 40p53 γ , Δ 133p53, Δ 133p53 β , Δ 133p53 γ , Δ p53, Δ p53 β and Δ p53 γ (7). As compared with the full length p53, the p53 β and p53 γ isoforms are produced by alternative splicing of intron 9, where 63 carboxyl-terminal amino-acid residues are replaced with 10 or 15 new residues. The Δ 133p53 isoform is transcribed by the P2 promoter and lacks 133 amino-terminal residues, including the entire transactivating domain and part of the DNA binding domain. The Δ 40p53 isoform is transcribed by the P1 or P1' promoter and lacks 40 amino-terminal residues, including the conservative Fxx Ψ W sequence, due to alternative splicing of intron 2. The Δ p53 isoform is produced by non-canonical splicing between exons 7 and 9, and lacks 66 residues in the DNA binding domain, including the highly conserved V region. The selection of different translation initiators may also produce more isoforms; for example, Δ 133p53 mRNA may be translated into either the Δ 133p53 or Δ 160p53 isoform (8).

It was previously reported that p53 isoforms have vital physical functions. Certain isoforms have been shown to be associated with the fine regulation of p53 activities, and are involved in apoptosis, cell cycle arrest and cellular senescence. Furthermore, the abnormal expression of p53 isoforms isolated

Correspondence to: Dr Wansheng Ji, Department of Gastroenterology, Affiliated Hospital of Weifang Medical University, 2428 Yuhe Road, Kuiwen, Weifang, Shandong 261031, P.R. China
E-mail: WanShengJI@126.com

*Contributed equally

Key words: B-cell lymphoma 2-associated X, gastric cancer, role, p53 β , p53

from *TP53* gene mutations is associated with the tumorigenesis of various tissues, including renal carcinoma (9), breast carcinoma (10), ovarian carcinoma (11), medulloblastoma (12), neuroblastoma (13), melanoma (14), squamous cell carcinoma (15), and medullar leukemia (16). p53 β has previously been shown to coordinate with wild-type p53 to work in a promoter-dependent manner, which helps induce apoptosis and inhibit proliferation, and is therefore associated with the control of carcinogenesis and drug resistance (13,14,17). The p53 status has been shown to differ in various gastric cancer cell lines: Wild-type p53 is expressed in MKN45 cells, but deleted in KATOIII cells (18), whereas mutated p53 is detected in SGC7901 cells (204 codon GAG→GCG mutation in the sixth exon, Glu→Ala) (19). The present study aimed to determine the function of p53 β in the inhibition of proliferation of cells expressing wild-type or mutated p53.

Materials and methods

Materials and agents. Cisplatin was purchased from Shandong Platinum Source Industry Co., Ltd. (Jinan, China). MTT, RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Jinan Kiagen Biology Technology Co., Ltd. (Jinan, China). TRIzol[®] RNA Extraction kit (batch number 14033089C), Reverse Transcription-Polymerase Chain Reaction (RT-PCR) kit (batch number A901KA241), primers, DNA marker (batch number 050714) and agarose (batch number 111860) were all purchased from Sangon Biotech Co., Ltd. (Shanghai, China). MyCycler[™] Thermal Cycler, BioSpectrum AC Gel Imaging system and EPS-301 Electrophoresis Meter were purchased from Bio-Rad Laboratories, Inc. (Hercules, CA, USA), UVP, Inc. (Upland, CA, USA) and GE Healthcare Life Sciences (Uppsala, Sweden), respectively.

Cell lines. The MKN45 (batch number CBP60488), SGC7901 (batch number CBP60500) and KATOIII (batch number CBP60483) human gastric cancer cell lines were supplied by the Cell Bank of Chinese Academy of Medical Science (Beijing, China), and had a passage number <10. All cell lines were tested for mycoplasma infection. The cells were cultured in RPMI-1640 medium supplemented with 10% FBS at 37°C in an atmosphere containing 5% CO₂. Cells in the exponential growth phase were used for the following experiments.

Measurement of p53 β and Δ 133p53 mRNA expression levels in gastric cancer cell lines. The MKN45, SGC-7901 and KATOIII cells were isolated in the exponential growth phase. mRNA extraction and cDNA synthesis were performed according to manufacturer's instructions of the TRIzol[®] and RT-PCR kits. Nested PCR was performed to amplify p53 β and Δ 133p53, and the primers used were as follows: p53 β outer primer forward, 5'-GTCAGTCCATGGAGGAGCCGCA-3' and reverse, 5'-GACGCACACATTGCAAGCAAGGGTTC-3'; p53 β internal primer forward, 5'-ATGGAGGAGCCGAGTCAAT-3' and reverse, 5'-TTTGAAAGCTGGTCTGGTCTGA-3'; Δ 133p53 outer primer forward, 5'-CTGAGGTGTAGAGCCAACTCTCTAG-3' and reverse, 5'-AGTCAGTCTGAGTCAAGCCCTTCTGTC-3'; Δ 133p53 internal primer forward, 5'-GCTAGTGGGTTGCAGGAGGTGCTTACAC-3' and

reverse, 5'-CTCACGCCCCACGGATCTGA-3'; β -actin primer forward, 5'-GTGGGGCGCCCCAGGCACCA-3' and reverse, 5'-CTCCTTAATGTCACGCACGATTTC-3'. The lengths of the amplified products were 1050 bp for p53 β , 750 bp for Δ 133p53, and 539 bp for β -actin. PCR conditions were set as 35 cycles at 94°C for 1 min for denaturation, 58°C for 50 sec for annealing and 72°C for 1 min for extension. The PCR products were subsequently analyzed by 2% agarose gel electrophoresis. The results were scanned and recorded by the Biospectrum AC Gel Imaging system (Alpha Innotech Corp., San Leandro, CA, USA).

MTT analysis of gastric cancer cell proliferation. The MKN45 and SGC-7901 cells were isolated in the exponential growth phase and seeded in a 96-well plate (5×10³ cell/well). The cells were then cultured for 24 h. Cisplatin (1, 2 or 4 μ mol/l) or an equal volume of phosphate-buffered saline (PBS) was added to the cells, which were cultured for a further 48 h. Subsequently, the culture medium was discarded and 20 μ l MTT solution (5 g/l) and 180 μ l fresh RPMI-1640 medium were added to the cells, which were cultured for another 4 h. The supernatant was then discarded, dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO, USA) was added to the cells (150 μ l/well) and the plate was oscillated for 10 min. The optical density (OD) of the cells was measured at a wavelength of 490 nm using a Multiskan FC microplate reader (Thermo Fisher Scientific, Inc., Waltham, MA, USA), and the rate of proliferation inhibition was calculated.

Assessment of p53, p53 β and Bax mRNA expression levels by RT-PCR analysis. The MKN45 and SGC-7901 cells were isolated in the exponential growth phase and seeded in a 96-well plate (5×10³ cells/well). Cisplatin (1, 2 or 4 μ mol/l) or an equal volume of PBS was added to the cells, which were then cultured for 24 h. The cells were then collected and mRNA extraction, cDNA synthesis and PCR amplification were performed according to the manufacturer's instructions of the TRIzol[®] and RT-PCR kits. The purity and quantity of RNA were analyzed using a 2000c UV-Vis Spectrophotometer (Thermo Fisher Scientific, Inc.). The following primers were used in the RT-PCR in the present study: p53 forward, 5'-GGTCTCCTCCACCGCTTCTTG TC-3' and reverse, 5'-GGCCTCATCTTGGGCCTGTGT-3'; p53 β forward, 5'-GTCACTGCCATGGAGGAGCCGCA-3' and reverse, 5'-ATGGAGGAGCCGAGTCAGAT-3'; Bax forward, 5'-ACCAAGAAGCTGAGCGAGTGTC-3' and reverse, 5'-ACAAAGATGGTCACGGTCTGCC-3'; β -actin forward, 5'-GAGCCACATCGCTCAGACAC-3' and reverse, 5'-TCGAGGAAACAAATTAAGAA-3'. The lengths of the amplified products were 690 bp for p53, 1050 bp for p53 β , 365 bp for Bax, and 539 bp for β -actin. PCR conditions were set as 35 cycles at 94°C for 5 min, 94°C for 30 sec, 55-58°C for 30 sec and 72°C for 30 sec, followed by 72°C for 10 min. The PCR products were subsequently analyzed by 2% agarose gel electrophoresis. The results were scanned and recorded by the Biospectrum AC Gel Imaging system.

Statistical analysis. SPSS version 17.0 (International Business Machines, Armonk, NY USA) software package was used for all statistical analyses. Comparisons between the measurement data were analyzed by one-way analysis of variance (ANOVA) and correlations between the data were determined by a linear

Table I. Inhibition of MKN45 and SGC7901 gastric cancer cell proliferation by cisplatin.

Cell line	Dose of cisplatin ($\mu\text{mol/l}$)				<i>F</i>	P-value
	0	1	2	4		
MKN45	0.236 \pm 0.007	0.200 \pm 0.003	0.165 \pm 0.004	0.117 \pm 0.009	49.768	<0.001
SGC7901	0.269 \pm 0.023	0.210 \pm 0.006	0.196 \pm 0.004	0.156 \pm 0.005	52.357	<0.001

Optical density is shown; values are expressed as the mean \pm standard deviation (n=5).




Figure 1. Diagrams of the (A) gene structure of *TP53* and (B) isoforms of p53.

regression ANOVA. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

mRNA expression levels of p53 β and $\Delta 133\text{p}53$ in the three gastric cancer cell lines. p53 β and $\Delta 133\text{p}53$ mRNA was expressed in the MKN45 cell line, whereas only p53 β mRNA was expressed in the SGC-7901 cells (Fig. 2). Neither p53 β nor $\Delta 133\text{p}53$ mRNA was expressed in the KATOIII cell line.

Inhibition of MKN45 and SGC7901 cell proliferation by treatment with different doses of cisplatin. Following a 48-h treatment with various doses of cisplatin, the OD value of MKN45 and SGC-7901 cells in the MTT assay was significantly reduced ($F_{\text{MKN45}} = 49.768$, $P < 0.001$; $F_{\text{SGC7901}} = 52.357$, $P < 0.001$) (Table I).

mRNA expression levels of p53 β , p53 and Bax in the cisplatin-treated cell lines. p53 β , p53 and Bax mRNA expression levels were detected in the control and cisplatin-treated groups. In the MKN45 cell line, the expression levels of p53 β , p53

and Bax mRNA increased with increasing doses of cisplatin (Fig. 3A). The linear regression ANOVA demonstrated that the expression of p53 β was positively correlated with the expression of p53 (n=4, $r = 0.976$, $t_r = 6.358$, $P < 0.05$, $y = 0.1362 + 3.217x$) (Fig. 4A). The expression of p53 β was also positively correlated with the expression of Bax (n=4, $r = 0.985$, $t_r = 8.023$, $P < 0.05$, $y = 0.423 + 2.792x$). In the SGC-7901 cell line, the mRNA expression levels of p53 β , p53 and Bax were not affected by cisplatin at the doses used (Fig. 3B). The linear regression ANOVA demonstrated that the expression of p53 β was positively correlated with the expression of p53 (n=4, $r = 0.999$, $t_r = 26.41$, $P < 0.01$, $y = 0.0004 + 0.999x$) (Fig. 4B); however, the expression of p53 β was not correlated with the expression of Bax (n=4, $r = -0.067$, $t_r = 0.095$, $P > 0.05$, $y = 0.948 - 0.135x$).

Discussion

Genomic instability, caused by mutations of the *TP53* gene, is widely accepted as a critical event in the carcinogenesis of numerous types of tumor. Furthermore, previous studies have indicated that the p53 isoforms have pivotal roles in various




Figure 2. Differential mRNA expression levels of p53 isoforms in MKN45, SGC-7901 and KATOIII human gastric cancer cell lines. Left, RNA extract from the gastric cancer cells; middle, p53 β expression in the gastric cancer cells; right, Δ 133p53 expression in the gastric cancer cells. Lane 1, DNA marker; lane 2, MKN45 cells; lane 3, SGC7901 cells; lane 4, KATOIII cells.




Figure 3. mRNA expression levels of p53, p53 β and Bax in MKN45 and SGC7901 human gastric cancer cells treated with cisplatin. Lane 1, DNA marker; lanes 2 and 6, cells prior to treatment with cisplatin; lanes 3 and 7, cells treated with 1 μ mol/l cisplatin; lanes 4 and 8, cells treated with 2 μ mol/l cisplatin; lanes 5 and 9, cells treated with 4 μ mol/l cisplatin. Bax, B-cell lymphoma 2-associated X protein.




Figure 4. Correlations between the mRNA expression levels of p53 β and p53, and p53 β and Bax in (A) MKN45 and (B) SGC7901 human gastric cancer cells treated with cisplatin. Bax, B-cell lymphoma 2-associated X protein.

physical and pathological processes. These findings suggested that novel isoform-based gene diagnosis and biological therapy may potentially be developed (10,11,13,15,16,20-23). In previous studies, all p53 isoforms were detected in tissue from superficial gastritis, atrophic gastritis, para-cancerous area, to advanced gastric carcinoma (24,25).

In the present study, mRNA expression levels of p53, p53 β and Bax were determined in order to analyze the correlation between p53 β and full-length p53, and between p53 β and Bax

in the cells expressing wild-type or mutated p53. In the MKN45 cells (wild-type p53), p53 β and Δ 133p53 mRNA was detected, whereas only p53 β mRNA was detected in the SGC7901 cells. Neither p53 β nor Δ 133p53 mRNA was detected in the KATOIII cells. Results of previous studies have indicated that the Δ 133p53 isoform has oncogenic effects (22,23,26), whereas the p53 β isoform acts as a tumor suppressor gene (13,27). Of note, these results suggested that gastric carcinogenesis may be caused by deletion of the *TP53* gene (KATOIII), muta-

tions of the *TP53* gene (SGC7901) or abnormal expression of p53 isoforms (MKN45). However, the initial results of the present study require further clarification in order to improve knowledge regarding p53-based carcinogenesis, diagnosis and biological therapy.

The growth of MKN45 and SGC7901 gastric cancer cell lines was significantly inhibited by treatment with cisplatin in a dose-dependent manner. Of note, p53 β had different roles in the two cell lines. In the MKN45 cell line (expressing wild-type p53), the mRNA expression levels of p53 β , p53 and Bax were increased accordingly with the dose of cisplatin, and the linear regression ANOVA indicated that the expression of p53 β had a positive linear correlation with the expression of p53 and Bax. However, in the SGC-7901 cell line (expressing mutated p53), the mRNA expression levels of p53 β , p53 and Bax were not affected by the dose of cisplatin, and the linear regression ANOVA analysis indicated that the expression of p53 β was significantly correlated with the expression of p53; however, p53 β was not correlated with the expression of Bax. Previous studies have shown that p53 β can work with full-length p53 in a promoter-dependent manner in order to selectively initiate the transcription of Bax, but not MDM2 (17). The results of the present study indicate the existence of a complex regulatory loop between p53 and its downstream target molecules, in which various p53 isoforms may be involved (28,29). Although the expression levels of p53 β were associated with the expression of full-length p53 in wild-type and mutated cell lines, only in the cells expressing wild-type p53 could p53 β coordinate with p53 and promote the transcription of Bax. In the cells expressing mutated p53, p53 β may lose its effects on target gene transcription, apoptosis and proliferative senescence.

In conclusion, based on the p53 status, gastric carcinogenesis may be caused by the deletion, mutation or abnormal expression of p53 isoforms. In cells expressing mutated p53, the p53 β isoform lost its effects on the transcription of Bax. Further knowledge regarding the p53 status is required in order to potentially produce p53-based gene diagnosis and individual biological therapy for gastric cancer.

Acknowledgements

The present study was supported by the Shandong Provincial Award Foundation for Youth and Middle-aged Scientists (grant no. BS2010WS034).

References

1. Tsui KC, Chiang TH, Wang JS, *et al*: Flavonoids from *Gynostemma pentaphyllum* exhibit differential induction of cell cycle arrest in H460 and A549 cancer cells. *Molecules* 19: 17663-17681, 2014.
2. Liu W, Lu X, He G, *et al*: Protective roles of Gadd45 and MDM2 in blueberry anthocyanins mediated DNA repair of fragmented and non-fragmented DNA damage in UV-irradiated HepG2 cells. *Int J Mol Sci* 14: 21447-21462, 2013.
3. Yasui Y, Hosokawa M, Sahara T, *et al*: Bitter gourd seed fatty acid rich in 9c, 11t, 13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells. *Prostaglandins Leukot Essent Fatty Acids* 73: 113-119, 2005.
4. Aoubala M, Murray-Zmijewski F, Khoury MP, *et al*: p53 directly transactivates $\Delta 133p53\alpha$, regulating cell fate outcome in response to DNA damage. *Cell Death Differ* 18: 248-258, 2011.
5. Sauer M, Bretz AC, Beinoraviciute-Kellner R, *et al*: C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity. *Nucleic Acids Res* 36: 1900-1912, 2008.
6. Courtis S, Verhaegh G, North S, *et al*: DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. *Oncogene* 21: 6722-6728, 2002.
7. Chan WM and Poon RY: The p53 Isoform Deltap53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity. *Cancer Res* 67: 1959-1969, 2007.
8. Marcel V, Perrier S, Aoubala M, *et al*: $\Delta 160p53$ is a novel N-terminal p53 isoform encoded by $\Delta 133p53$ transcript. *FEBS Lett* 584: 4463-4468, 2010.
9. Song W, Huo SW, Lü JJ, *et al*: Expression of p53 isoforms in renal cell carcinoma. *Chin Med J (Engl)* 122: 921-926, 2009.
10. Bourdon JC, Khoury MP, Diot A, *et al*: p53 mutant breast cancer patients expressing p53 γ have as good a prognosis as wild-type p53 breast cancer patients. *Breast Cancer Res* 13: R7, 2011.
11. Chambers SK and Martinez JD: The significance of p53 isoform expression in serous ovarian cancer. *Future Oncol* 8: 683-686, 2012.
12. Philipova T, Baryawno N, Hartmann W, *et al*: Differential forms of p53 in medulloblastoma primary tumors, cell lines and xenografts. *Int J Oncol* 38: 843-849, 2011.
13. Goldschneider D, Horvilleur E, Plassa LF, *et al*: Expression of C-terminal deleted p53 isoforms in neuroblastoma. *Nucleic Acids Res* 34: 5603-5612, 2006.
14. Avery-Kiejda KA, Zhang XD, Adams LJ, *et al*: Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. *Clin Cancer Res* 14: 1659-1668, 2008.
15. Boldrup L, Bourdon JC, Coates PJ, Sjöström B and Nylander K: Expression of p53 isoforms in squamous cell carcinoma of the head and neck. *Eur J Cancer* 43: 617-623, 2007.
16. Anensen N, Hjelle SM, Van Belle W, *et al*: Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. *Oncogene* 31: 1533-1545, 2012.
17. Bourdon JC, Fernandes K, Murray-Zmijewski F, *et al*: p53 isoforms can regulate p53 transcriptional activity. *Genes Dev* 19: 2122-2137, 2005.
18. Bernard H, Garmy-Susini B, Ainaoui N, *et al*: The p53 isoform, $\Delta 133p53\alpha$, stimulates angiogenesis and tumour progression. *Oncogene* 32: 2150-2160, 2013.
19. Sigal A and Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. *Cancer Res* 60: 6788-6793, 2000.
20. Terrier O, Marcel V, Cartet G, *et al*: Influenza A viruses control expression of proviral human p53 isoforms p53 β and $\Delta 133p53\alpha$. *J Virol* 86: 8452-8460, 2012.
21. Campbell HG, Slatyer TL, Jeffs A, *et al*: Does $\Delta 133p53$ isoform trigger inflammation and autoimmunity? *Cell Cycle* 11: 446-450, 2012.
22. Berglind H, Pawitan Y, Kato S, Ishioka C and Soussi T: Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. *Cancer Biol Ther* 7: 699-708, 2008.
23. Hofstetter G, Berger A, Schuster E, *et al*: $\Delta 133p53$ is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. *Br J Cancer* 105: 1593-1599, 2011.
24. Solomon H, Sharon M and Rotter V: Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53 β and p53 γ . *Cell Death Differ* 21: 1347-1349, 2014.
25. Marcel V, Fernandes K, Terrier O, Lane DP and Bourdon JC: Modulation of p53 β and p53 γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. *Cell Death Differ* 21: 1377-1387, 2014.
26. Hofstetter G, Berger A, Berger R, *et al*: The N-terminally truncated p53 isoform $\Delta 40p53$ influences prognosis in mucinous ovarian cancer. *Int J Gynecol Cancer* 22: 372-379, 2012.
27. Graupner V, Schulze-Osthoff K, Essmann F and Jänicke RU: Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. *Cell Cycle* 8: 1238-1248, 2009.
28. Camus S, Ménendez S, Fernandes K, *et al*: The p53 isoforms are differentially modified by Mdm2. *Cell Cycle* 11: 1646-1655, 2012.
29. Marine JC and Lozano G: Mdm2-mediated ubiquitylation: p53 and beyond. *Cell Death Differ* 17: 93-102, 2010.